CA2368242A1 - Combination therapy for treating glaucoma - Google Patents

Combination therapy for treating glaucoma Download PDF

Info

Publication number
CA2368242A1
CA2368242A1 CA002368242A CA2368242A CA2368242A1 CA 2368242 A1 CA2368242 A1 CA 2368242A1 CA 002368242 A CA002368242 A CA 002368242A CA 2368242 A CA2368242 A CA 2368242A CA 2368242 A1 CA2368242 A1 CA 2368242A1
Authority
CA
Canada
Prior art keywords
iop
lowering agent
alkyl
glutamate
glutamate antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002368242A
Other languages
English (en)
French (fr)
Inventor
Louis Desantis Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2368242A1 publication Critical patent/CA2368242A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002368242A 1999-03-12 1999-03-12 Combination therapy for treating glaucoma Abandoned CA2368242A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/005423 WO2000054810A1 (en) 1999-03-12 1999-03-12 Combination therapy for treating glaucoma

Publications (1)

Publication Number Publication Date
CA2368242A1 true CA2368242A1 (en) 2000-09-21

Family

ID=22272341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002368242A Abandoned CA2368242A1 (en) 1999-03-12 1999-03-12 Combination therapy for treating glaucoma

Country Status (5)

Country Link
EP (1) EP1169061A1 (zh)
AU (1) AU3082999A (zh)
CA (1) CA2368242A1 (zh)
HK (1) HK1040184A1 (zh)
WO (1) WO2000054810A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
JP2008507557A (ja) * 2004-07-22 2008-03-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 眼疾患の治療法
JP2008507588A (ja) * 2004-07-26 2008-03-13 アラーガン、インコーポレイテッド 眼の病態を処置する方法
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
US20070167527A1 (en) * 2006-01-13 2007-07-19 Burke James A Memantine for the normalization of visual acuity deficits
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
CA2807081C (en) 2010-07-29 2018-09-18 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
JP2021531327A (ja) * 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 眼圧降下剤、cnp化合物、nrp−b化合物、tie−2アゴニスト、または神経栄養剤を含む、緑内障または高眼圧症を治療するための徐放性薬剤送達系

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma

Also Published As

Publication number Publication date
WO2000054810A1 (en) 2000-09-21
HK1040184A1 (zh) 2002-05-31
AU3082999A (en) 2000-10-04
EP1169061A1 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
US6441047B2 (en) Combination therapy for treating glaucoma
CA2368242A1 (en) Combination therapy for treating glaucoma
KR100452715B1 (ko) 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
JP2007217437A (ja) カリウムチャンネル遮断剤の投与により、哺乳動物の眼圧を降下する方法
AU704938B2 (en) Combination therapy for treating glaucoma
US6264935B1 (en) Ophthalmic composition containing a carbonic anhydrase inhibitor and xanthan gum
US6545045B1 (en) Prostaglandin E agonists for treatment of glaucoma
EP0672417A1 (en) Reduction of elevated intraocular pressure
EP1267847B1 (en) 5ht 2 agonists for controlling iop and treating glaucoma
US6200990B1 (en) Neuroprotective agents having antioxidant and NMDA antagonist activity
US5578638A (en) Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
EP1647274A1 (en) Remedy for pruritus comprising piperidine derivative as the active ingredient
EP3730137B1 (en) Therapeutic agent for glaucoma comprising an fp agonist and timolol
AU2004214563A1 (en) Combination therapy for treating glaucoma
US5308849A (en) Method of reducing elevated intraocular pressure
AU2001217709B2 (en) Combination therapy for lowering and controlling intraocular pressure
EP0728480A1 (en) Use of ifenprodil for treatment of elevated intraocular pressure
US6927233B1 (en) 5ht2 agonists for controlling IOP and treating glaucoma
AU2001217709A1 (en) Combination therapy for lowering and controlling intraocular pressure
EP0277814B1 (en) Anti-glaucoma use of trifluoromethanesulfonamide
AU716577B2 (en) Use of polyamine antagonists for the treatment of glaucoma
EP0607697A2 (en) DILAZEP for reduction of elevated intraocular pressure
US20040058976A1 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead